Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors
Open Access
- 20 June 2011
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (5), 787-792
- https://doi.org/10.3892/etm.2011.291
Abstract
Bronchopulmonary neuroendocrine tumors (BP-NETs) are separated into four subgroups: typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC). The signaling pathway involving AKT/mammalian target of rapamycin (mTOR) is crucial to the regulation of cell growth, proliferation and survival, and is frequently activated in human cancers. Consequently, mTOR is considered an attractive target for anticancer agents. The present study aimed to evaluate the expression of phosphorylated AKT and mTOR in a series of BP-NETs, and to analyze the correlations with clinicopathological parameters. p-AKT and p-mTOR levels were determined by immunohistochemistry in a series of 210 BP-NETs, including 85 SCLCs, 17 LCNECs, 26 ACs, 75 TCs and 7 tumorlets. Higher p-AKT and p-mTOR expression levels were identified in the majority of tumorlets and carcinoids in comparison to the LCNECs (P=0.0001) and SCLCs (P=0.0002). Furthermore, a significant association was observed between p-mTOR expression and tumor size (T) in SCLCs (P=0.04) and LCNECs (P=0.03): T3-T4 tumors exhibited significantly lower p-mTOR expression compared to T1-T2 tumors. In conclusion, most of the BP-NETs examined in this study expressed p-AKT and p-mTOR, suggesting that the AKT/mTOR pathway plays an important role in these tumors. Additionally, our results confirm that low- to intermediate-grade tumors are more closely associated to each other than to high-grade tumors, despite sharing common classification and a common origin from neuroendocrine cells. These findings improve our knowledge of the biological characterization of these tumors and indicate new therapeutic opportunities for the treatment of BP-NETs.Keywords
This publication has 28 references indexed in Scilit:
- AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001Clinical Cancer Research, 2009
- Bronchopulmonary neuroendocrine tumorsCancer, 2008
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- Neuroendocrine Neoplasms of the Lung: A Prognostic SpectrumJournal of Clinical Oncology, 2006
- Upstream and downstream of mTORGenes & Development, 2004
- The tor pathway: a target for cancer therapyNature Reviews Cancer, 2004
- The Surgical Spectrum of Pulmonary Neuroendocrine NeoplasmsChest, 2001
- Genetic changes in the spectrum of neuroendocrine lung tumorsCancer, 1999
- Survival Analysis of 200 Pulmonary Neuroendocrine Tumors With Clarification of Criteria for Atypical Carcinoid and Its Separation From Typical CarcinoidThe American Journal of Surgical Pathology, 1998
- Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lungHuman Molecular Genetics, 1997